Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 55 Small Cell Lung Carcinoma 39 Lung Neoplasms 30 Carcinoma, Ovarian Epithelial 29 Neuroblastoma 25 Fallopian Tube Neoplasms 23 Uterine Cervical Neoplasms 18 Neoplasms 18 Leukemia 18 Leukemia, Myeloid, Acute 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Sarcoma 10 Lymphoma 10 Brain Neoplasms 9 Recurrence 8 Carcinoma, Non-Small-Cell Lung 8 Unspecified Adult Solid Tumor, Protocol Specific 7 Neoplasm Metastasis 7 Myelodysplastic Syndromes 7 Burkitt Lymphoma 7 Blast Crisis 7 Neuroectodermal Tumors, Primitive, Peripheral 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Follicular 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myelomonocytic, Acute 6 Leukemia, Monocytic, Acute 6 Leukemia, Megakaryoblastic, Acute 6 Leukemia, Erythroblastic, Acute 6

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Topotecan × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡